The Definition of Half Liquid Is Only Half Baked
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
IBSA INSTITUT BIOCHIMIQUE, S.A. V. TEVA PHARMACEUTICALS USA, INC.
Before Prost, Reyna, and Hughes. Appeal from the District Court of Delaware
Summary: A term may be indefinite when the proposed construction is not supported by the record and the meaning is not reasonably ascertainable from the record.
Teva Pharmaceuticals USA, Inc. (“Teva”) sought to market a generic version of a drug sold by IBSA Institut Biochimique, S.A., Altergon, S.A., and IBSA Pharma Inc. (collectively “IBSA”). In response, IBSA sued Teva for infringement of its U.S. Patent No. 7,723,390 (the ’390 patent) in the U.S. District Court for the District of Delaware. The District Court found the ’390 patent invalid because the claimed term “half-liquid” was indefinite. IBSA appealed.
Reviewing determinations about legal standards and intrinsic evidence de novo and factual findings based on extrinsic evidence for clear error, the Federal Circuit affirmed the District Court’s decision. In particular, the Federal Circuit could not construe “half-liquid” to mean “semi-liquid,” as IBSA had argued. First, the Federal Circuit determined that the meaning of “half-liquid” was not reasonably clear from the claims. Next, turning to the specification, the Federal Circuit found that language listing “half-liquid” separately from gels and pastes indicated that a “half-liquid” is not necessarily a gel or paste. IBSA’s construction, however, encompassed gels and pastes as “half-liquids.” Looking next at the prosecution history, the Federal Circuit explained that, while an Italian patent – to which the ’390 patent claimed priority – used the word “semiliquido” or “semi-liquid” similarly to the ’390 patent’s use of “half-liquid,” the terms could not have the same meaning in the ’390 patent. The ’390 patent used both the term “half-liquid” and the term “semi-liquid” in its claims. Moreover, differences in language between the certified translation of the Italian application and the ’390 patent suggested that the discrepancy in usage was intentional, implying that the different word choice of “half-liquid” and “semi-liquid” results in a different scope. Finally, turning to extrinsic evidence, the Federal Circuit highlighted the inability of IBSA’s expert witness to define “half-liquid” and the term’s absence from technical dictionaries. Accordingly, the Federal Circuit found no clear error in the District Court’s determination that the record does not supply “half-liquid” with a definite meaning and affirmed the judgment.
Editor: Paul Stewart
Written by: Matthew Friedrichs & Karen Cassidy
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…